Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: Evaluation by in vitro probe acylcarnitine assay
Keywords: Mitochondrial fatty acid oxidation disorder; Bezafibrate; New treatment; Hypolipidemic drug; In vitro probe acylcarnitine assay; Peroxisome proliferation activator receptor;